SCM
LXEO icon

Sterling Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Sterling Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65K Sell
1,429
-762
-35% -$4.12K ﹤0.01% 2459
2026
Q1 		$12.6K Sell
2,191
-1,445
-40% -$10.2K ﹤0.01% 2257
2025
Q4 		$36.1K Buy
3,636
+1,903
+110% +$17.4K ﹤0.01% 1933
2025
Q3 		$11.5K Buy
1,733
+1,088
+169% +$5.26K ﹤0.01% 2416
2025
Q2 		$2.59K Buy
645
+618
+2,289% +$2.03K ﹤0.01% 2845
2025
Q1 		$94 Hold
27
– – ﹤0.01% 3148
2024
Q4 		$178 Hold
27
– – ﹤0.01% 3127
2024
Q3 		$244 Buy
+27
New +$322 ﹤0.01% 3084

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Sterling Capital Management's LXEO Position: Q2 2026 in Review

Sterling Capital Management reduced its Lexeo Therapeutics (LXEO) stake by 35% in Q2 2026, selling an estimated $4.12K and leaving 1,429 shares worth $6.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

Sterling Capital Management first reported a position in LXEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $36.1K in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Sterling Capital Management held 1,429 shares of Lexeo Therapeutics worth $6.65K as of Q2 2026.
  • Sterling Capital Management sold 762 Lexeo Therapeutics shares in Q2 2026, an estimated $4.12K.
  • Lexeo Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2459 holding.
  • Sterling Capital Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Lexeo Therapeutics position peaked at $36.1K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.